Uterine response to estradiol under action of chorionic gonadotropin in mice.
This work examined the effect of chorionic gonadotropin on proliferative and morphogenetic reactions in the uterus under short- and long-term estrogen treatments. Ovariectomized mice received a single injection with estradiol dipropionate (2 micro g per 100 g; subcutaneously, sc) or vehicle and injections with human chorionic gonadotropin (10 IU per 100 g; sc) or vehicle twice a day for 2 days. Other groups of animals received injections with estradiol once a week or vehicle and injections with chorionic gonadotropin or vehicle once a day for 30 days. The uteri were removed 48 h after the last estradiol or vehicle injection. In animals treated with estradiol and chorionic gonadotropin for a month, the incidence of atypical endometrial hyperplasia was significantly higher. In animals treated with estradiol and chorionic gonadotropin for 2 days or for a month, uterine mass was slightly increased, the number of mitotic cells and BrdU-labeled cells was greater in luminal epithelium, glandular epithelium, stromal and myometrial cells, whereas the expression of estrogen receptors-alpha was lower in all uterine compartments, than in control. In mice who received estradiol and chorionic gonadotropin for 2 days, levels of beta-catenin and glycogen synthase kinase-3beta in luminal and glandular epithelia were lower. In animals treated with estradiol and chorionic gonadotropin for a month, the level of beta-catenin was slightly higher, and the expression of glycogen synthase kinase-3beta was lower in luminal and glandular epithelia. Thus, chorionic gonadotropin exerts estradiol-induced proliferative and morphogenetic changes in the uterus. This action of chorionic gonadotropin is associated with decreased expression of estrogen receptors-alpha and with changes in expression of beta-catenin and glycogen synthase kinase-3beta in the uterus.
Gunin
A G
AG
Department of Histology, Medical School, Chuvash State University, Cheboksary, Russia. drgunin@mail.ru
Emelianov
V U
VU
Mironkin
I U
IU
Morozov
M P
MP
Ivanov
V A
VA
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D001707:Biopsy, Needle; D006063:Chorionic Gonadotropin / Q000494:pharmacology*; D003598:Cytoskeletal Proteins / Q000032:analysis; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004347:Drug Interactions; D004714:Endometrial Hyperplasia / Q000209:etiology* / Q000473:pathology*; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D038341:Glycogen Synthase Kinases / Q000032:analysis; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D051379:Mice; D008815:Mice, Inbred Strains; D010052:Ovariectomy; D011897:Random Allocation; D012016:Reference Values; D012680:Sensitivity and Specificity; D015534:Trans-Activators / Q000032:analysis; D014599:Uterus / Q000187:drug effects / Q000473:pathology; D051176:beta Catenin
D015415:Biomarkers; C495267:CTNNB1 protein, mouse; D006063:Chorionic Gonadotropin; D003598:Cytoskeletal Proteins; D015534:Trans-Activators; D051176:beta Catenin; D004958:Estradiol; D038341:Glycogen Synthase Kinases